SEC Filing Summary: Novus Therapeutics, Inc. (NVUS)
Business Context and Reporting Period
This Form 8-K was filed by Novus Therapeutics, Inc. on February 6, 2020. The registrant is a Delaware corporation with its principal executive offices in Irvine, California. The filing addresses a specific regulatory matter regarding the company's continued listing on the Nasdaq Capital Market. Note: The request metadata referenced "Eledon Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as Novus Therapeutics, Inc.
Key Financial Metrics
This filing is a current report regarding listing status and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Listing Status
- Previous Notice: On August 8, 2019, the company received notice from Nasdaq regarding non-compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)), which mandates a minimum closing bid price of $1.00 per share for 30 consecutive business days.
- Current Determination: On February 6, 2020, Nasdaq granted the company an additional 180-day extension to regain compliance.
- Compliance Deadline: The extension period ends on August 3, 2020.
- Compliance Criteria: To maintain listing status, the closing bid price of the common stock must reach at least $1.00 per share for a minimum of 10 consecutive business days prior to the August 3, 2020 deadline.
- Immediate Impact: The extension letter does not impact the company's current listing on the Nasdaq Capital Market.
Outlook, Risks, and Contingencies
The primary risk identified is the potential delisting if the company fails to meet the $1.00 minimum bid price requirement within the extended timeframe. Management commentary is limited to the notification of the extension and the specific requirements to regain compliance. No other risks, contingencies, or unusual items are disclosed in this specific filing.
Investor Verification Checklist
- Verify the current trading price of NVUS common stock relative to the $1.00 threshold.
- Monitor the stock's closing bid price over the next 10 consecutive business days to assess progress toward compliance.
- Confirm the final compliance deadline of August 3, 2020, and watch for subsequent filings if the target is not met.
- Review prior filings (e.g., 10-K or 10-Q) for financial health metrics, as this 8-K contains no financial data.